KRAS and pancreatic neoplasm: It has been reported that oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function and that resistance to KRAS-targeted therapy might be mediated by a subset of tumor cells that depend on oxidative phosphorylation for survival instead of the classic Warburg effect (Viale et al., 2014).